Vera Therapeutics, Inc (VERA) Stock Analysis
Verdict: WATCH (do not buy)
Binary Phase 3 Atacicept data will dictate a 10x valuation swing; current 13.6x current ratio buys time, but insider selling is a red flag.
Investment score: 58/100
Analysis as of
Is Vera Therapeutics, Inc stock worth reviewing? AI model thesis
A high-risk, high-reward biotech with a solid balance sheet but poor insider sentiment.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Vera Therapeutics, Inc opportunities and risks
What speaks for VERA
- Phase 3 Data Inflection
What speaks against VERA
- Negative Insider Momentum
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| VERA | n/a | 0.0x | n/a | 0.0% | 0.0% | -9.5% |
| IRON | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.1% |
| KLRA | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.4% |
| NRIX | n/a | 28.8x | n/a | -139.4% | -411.4% | -13.2% |
| BCRX | n/a | 2.3x | n/a | 18.9% | -51.7% | 14.7% |
| IMNM | n/a | 501.0x | n/a | -1161.9% | -5593.8% | -10.2% |
| Peer median | n/a | 2.3x | n/a | 0.0% | -51.7% | -7.1% |
Frequently asked questions about Vera Therapeutics, Inc (VERA)
Is VERA stock a good investment?
The cached TradeMates AI model rates Vera Therapeutics, Inc as WATCH (do not buy) with an investment score of 58/100. A high-risk, high-reward biotech with a solid balance sheet but poor insider sentiment. This is algorithmic model output, not personal investment advice.
Is VERA stock a buy?
The TradeMates model verdict for VERA is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.